StreetInsider.com News Articles

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

The analyst commented: "Look for Biotech to Outperform through YE:26 with Multiple Value Driving Events; Biotech had a strong summer exemplified by Moderna's (MRNA) 177% single day move on positive INTERpath-001 data. We expect Biotech to finish the year strong driven by commercial growth, validating clinical data, unprecedented innovation and continued M&A. We look for growth of Alnylam's (ALNY) AMVUTTRA, Legend's (LEGN) CARVYKTI and Mesoblast's (MESO) Ryoncil. Capricor (CAPR) has a November 22nd PDUFA date for deromicel in DMD, Moderna will present intismeran data, Arrowhead (ARWR) will file the sNDA for

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'

Tue, 01 Sep 2026 09:07:24 -0400

Piper Sandler analyst Edward A. Tenthoff previews year-end for Biotechnology.

H.C. Wainwright Reiterates Buy Rating on CRISPR Therapeutics (CRSP)

Mon, 31 Aug 2026 06:51:32 -0400

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented: "At the European Society of Cardiology (ESC), CRISPR Therapeutics presented updated follow-up from 15 Phase 1a patients, with the 0.8 mg/kg cohort (n=4) showing 78.6% ANGPTL3, 52.5% LDL-C, 47.8% TG, 37.2% ApoB, 52.0% non-HDL-C, and 71.7% TG-rich lipoprotein cholesterol reductions at one year. The prior high-dose dataset showed 73% ANGPTL3 lowering at Day 30 and 48.9% LDL-C/55.2% TG lowering at Day 60. ANGPTL3 suppression therefore deepened 5.6 points and LDL-C 3.6 points; TG gave back 7.4 points but remained nearly

CRISPR Therapeutics (CRSP) Reiterated at Market Outperform by Citizens on CTX310 Data

Mon, 31 Aug 2026 05:02:30 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $80.00 price target on CRISPR Therapeutics (NASDAQ: CRSP).

The analyst commented, "CRISPR Therapeutics AG presented longer-term durability data for CTX310, an ANGPTL3- targeting in vivo gene editor, at the European Society of Cardiology congress. CTX310 demonstrated lasting impact on both ANGPTL3 expression and several key CV biomarkers, supporting advancement into Ph1b in severe hypertriglyceridemia (sHTG). We believe the current early data points to ballpark results with ASO (monthly) or siRNA (quarterly) therapies with the benefit of a one-time administration. We maintain our Market Outperform rating and $80 DCF-derived price target."

For an

CRISPR Therapeutics reports one-year CTX310 lipid-lowering data

Fri, 28 Aug 2026 10:31:27 -0400

CRISPR Therapeutics (Nasdaq: CRSP) presented one-year follow-up data from its Phase 1a clinical trial of CTX310, an investigational in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3, at the European Society of Cardiology Congress 2026. The findings were simultaneously published in The New England Journal of Medicine.

The trial enrolled 15 participants across five dose cohorts ranging from 0.1 to 0.8 mg/kg. At the highest dose of 0.8 mg/kg, mean reductions from baseline at one year were 79% for circulating ANGPTL3 protein (maximum 89%), 48% for triglycerides (maximum 78%), and 53% for LDL cholesterol (maximum 84%). Reductions were described as dose-dependent and

CRISPR Therapeutics reports one-year CTX310 lipid-lowering data

Fri, 28 Aug 2026 10:31:27 -0400

CRISPR Therapeutics reports one-year CTX310 lipid-lowering data

Fri, 28 Aug 2026 10:31:27 -0400

CRISPR Therapeutics reports one-year CTX310 lipid-lowering data

Fri, 28 Aug 2026 10:31:27 -0400

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Fri, 28 Aug 2026 10:31:00 -0400

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

-Phase 1a clinical data for CTX310® continued to demonstrate robust, dose-dependent reductions in circulating ANGPTL3 with a mean reduction from baseline of 79% (maximum 89%), a mean reduction in triglycerides (TG) of 48% (maximum 78%), and a mean reduction of low-density lipoprotein (LDL) of 53% (maximum 84%) at the highest dose-

-CTX310 was well tolerated with no treatment-related serious adverse events, no ≥Grade 3 changes in liver transaminases, and no additional treatment-related adverse events since the previous update-

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Fri, 28 Aug 2026 10:31:00 -0400

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Fri, 28 Aug 2026 10:31:00 -0400

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Fri, 28 Aug 2026 10:31:00 -0400

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-

CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026

Fri, 28 Aug 2026 10:31:00 -0400

-Data presented in a late-breaking presentation at the European Society of Cardiology (ESC) Congress 2026-